Catumaxomab
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Catumaxomab: From Malignant Ascites to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Catumaxomab (DrugBank ID: DB06607) is a trifunctional anti-EpCAM × anti-CD3 bispecific antibody originally developed for malignant ascites caused by EpCAM-positive carcinomas. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy, but this prediction is currently supported by 0 clinical trials and 0 publications — it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Malignant Ascites (EpCAM-positive carcinoma) |
| Predicted New Indication | Severe Nonproliferative Diabetic Retinopathy |
| TxGNN Prediction Score | 99.64% (rank 4336) |
| Evidence Level | L5 |
| Finland Market Status | 未上市 (Not Marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data (original_moa) is flagged as a data gap in the source records. Based on the repurposing rationale available in the evidence pack, catumaxomab is known to be a trifunctional bispecific antibody that simultaneously binds EpCAM on tumor cells and CD3 on T-cells, recruiting cytotoxic T-cells and accessory immune cells (via its intact Fc region) to destroy EpCAM-positive tumor cells. Its original approved use was for malignant ascites in EpCAM-positive carcinomas.
Diabetic retinopathy — including the severe nonproliferative stage — is driven by a fundamentally different pathology: chronic hyperglycemia, VEGF-driven microvascular damage, retinal ischemia, and low-grade inflammation. There is no known overlap between T-cell-mediated tumor cytotoxicity and the metabolic/vascular processes underlying diabetic retinopathy.
The evidence pack's own mechanistic assessment explicitly flags this as a low-plausibility, speculative link: the prediction is driven entirely by the TxGNN graph model's score, with no supporting literature, clinical trials, or biological rationale identified. The same caveat applies to the two lower-ranked candidates (drug-induced osteoporosis, rank 2; diabetic retinopathy, rank 3), both of which also lack any mechanistic or clinical support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Finland Market Information
Catumaxomab is currently not marketed in Finland (0 approved authorizations on record); no license or product information is available for this candidate.
Cytotoxicity
Catumaxomab's original approved use (malignant ascites in EpCAM-positive carcinoma) qualifies it as an antineoplastic/immuno-oncology agent, so this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (T-cell-engaging trifunctional bispecific antibody), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has evidence level L5 — model prediction only, with zero supporting clinical trials or literature, and the evidence pack's own mechanistic analysis rates the biological plausibility as very low. Critical safety data (TFDA/Fimea package insert warnings and contraindications) is also flagged as a Blocking data gap, meaning no S1 safety pre-assessment can be performed yet.
To proceed, the following is needed:
- Package insert / regulatory label data (warnings, contraindications) to clear the Blocking safety gap (DG001)
- Confirmed mechanism of action from DrugBank to properly assess mechanistic plausibility (DG002)
- Emergence of preclinical, mechanistic, or clinical evidence specifically linking EpCAM×CD3-directed T-cell engagement to diabetic retinopathy pathology before this candidate can be re-scored above L5
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.